Calliditas Therapeutics Ab Is A Biopharmaceutical Company Based In Stockholmswedenfounded In 2004The Company Specializes In Developing And Commercializing Innovative Treatments For Orphan Diseasesparticularly Focusing On Renal And Hepatic Conditionscalliditas Aims To Meet Significant Unmet Medical Needs Across The United Stateseuropeand Asia The Company S Product Portfolio Includes Tarpeyonefecon An Oral Formulation Designed To Reduce Kidney Function Loss In Adults With Immunoglobulin A Nephropathywhich Received Fda Approval In December 2021Calliditas Is Also Advancing Setanaxiba Nox Inhibitor Currently In Clinical Trials For Various Conditionsincluding Primary Biliary Cholangitis And Solid Tumorsthe Company Has Established Partnerships With Organizations Like Everest Medicines And Stada To Enhance Its Market Presence And Has Reported Strong Financial Growthwith Revenues Projected To Reach 1 8 Billion Sek In 2024Under The Leadership Of Ceo Renee Aguiar Lucandercalliditas Is Dedicated To Delivering Life Changing Medications And Is Actively Seeking Individuals Who Share Its Mission To Improve The Lives Of Patients With Rare Diseases
